Abstract
Stent thrombosis is a morbid complication following percutaneous coronary intervention (PCI). Dual antiplatelet therapy significantly reduces stent thrombosis risk. However, the antiplatelet response to clopidogrel - the most frequently used ADP receptor antagonist in post-PCI patients - varies among individuals. High on-treatment platelet reactivity was repeatedly associated with the risk of stent thrombosis. Ticagrelor is a novel ADP receptor blocker that has shown greater, more rapid and more consistent platelet inhibition than clopidogrel. This agent offers a unique mechanism of action, no relevant pharmacological interactions, consistent platelet inhibition, and a good safety profile. This article reviews the prospective use of ticagrelor in the treatment of stent thrombosis in acute coronary syndrome patients undergoing PCI of culprit coronary lesion.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Acute Coronary Syndrome / pathology
-
Acute Coronary Syndrome / surgery
-
Adenosine / analogs & derivatives*
-
Adenosine / therapeutic use
-
Angioplasty, Balloon, Coronary / adverse effects*
-
Blood Platelets / drug effects
-
Blood Platelets / metabolism
-
Blood Platelets / pathology
-
Clopidogrel
-
Coronary Thrombosis / etiology
-
Coronary Thrombosis / pathology
-
Coronary Thrombosis / prevention & control*
-
Drug Resistance / drug effects
-
Humans
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Purinergic P2Y Receptor Antagonists / therapeutic use*
-
Receptors, Purinergic P2 / metabolism
-
Stents
-
Ticagrelor
-
Ticlopidine / analogs & derivatives*
-
Ticlopidine / therapeutic use
Substances
-
Platelet Aggregation Inhibitors
-
Purinergic P2Y Receptor Antagonists
-
Receptors, Purinergic P2
-
Clopidogrel
-
Ticagrelor
-
Adenosine
-
Ticlopidine